Abbott Laboratories’ Profit Rises 12%
- Share via
Abbott Laboratories’ second-quarter profit rose 12% as the company cut its research and interest expenses and sold more of its Kaletra HIV medicine and Flomax prostate drug.
Net income rose to $592.3 million, or 38 cents a share. Sales rose 5.3% to $4.32 billion.
Abbott last month cut its 2002 profit forecast, citing slowing sales of its Meridia obesity drug, and analysts said sales growth for the second quarter still fell short of some estimates.
Shares of Abbott Park, Ill.-based Abbott fell $2.01, or 6%, to $31.65 on the NYSE.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
